Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 2.56 +0.21 (8.94%)
price chart
Ahead of the Bell: Sunesis Pharma shares sink
Sunesis said it will seek marketing approval from European regulators and also will meet with the U.S. Food and Drug Administration to determine the "appropriate regulatory path forward.
An Insight Into Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)  Inside Trade
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin ...  MarketWatch
Related articles »  
UPDATE: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals (SNSS) to Buy ...
Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) gained Wednesday after being upgraded to Buy from Hold with a price target of $4 (from $2) by analyst Mara Goldstein of Cantor Fitzgerald.
Analyst Action: Spirit Airlines Incorporated (NASDAQ:SAVE), Sunesis ...  Stafford Daily
Sunesis Pharmaceuticals Receives Average Rating of �Hold� from Brokerages ...  WKRB News
Related articles »  
Morning Buzz: Cyren Ltd. (CYRN), Sunesis Pharmaceuticals (SNSS), 3D ...
Shares of Cyren Ltd. (CYRN) are surging 24% to $2.17 in pre-market trade after the company announced that China-based Bangcle, the world's largest mobile app security provider, will deploy Cyren's embedded technology to protect mobile apps against ...
Related articles »  
Sunesis Pharmaceuticals Stock Rating Upgraded by Roth Capital (SNSS)
Sunesis Pharmaceuticals, Inc. logo Roth Capital upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a neutral rating to a buy rating in a report released on Monday.
What's Hot: SeaDrill Limited (NYSE:SDRL), Sunesis Pharmaceuticals ...  Property Mentor
Related articles »  
Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday ...
SOUTH SAN FRANCISCO, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call and slide webcast on Tuesday, December 9, 2014 at 10:30 AM Pacific Time to discuss ...
Related articles »  
Sunesis Pharmaceuticals Upgraded to Buy by Roth Capital (SNSS)
Roth Capital's price objective would indicate a potential upside of 94.57% from the company's current price. SNSS has been the subject of a number of other recent research reports.
Stocks Under Review -BGC Partners, (BGCP), Entravision (EVC), Sunesis ...  Techsonian (press release)
Related articles »  
Notable Movers: Layne Christensen Company (NASDAQ:LAYN), Sunesis ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was upgraded to a buy rating by analysts at Cantor Fritzgerald. Analysts at Cantor Fritzgerald believe that the company provides prime value to investors going forward and the growth trajectory for the ...
Related articles »  
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session with its shares surging over 38% on the day.
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape  Nasdaq
Related articles »  
Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 ...
7, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be ...
Sunesis Pharmaceuticals (SNSS) to Present Phase 3 VALOR Trial Data at ASH  StreetInsider.com (subscription)
Sunesis counts on fresh look at trial data for leukemia drug win  San Francisco Business Times (blog)
Related articles »  
Biotech Stocks Jump On Some Enormous News: Sunesis Pharmaceuticals, Inc ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) soared 38.32% yesterday after the company declared that results from the company's phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia will be ...
Healthcare Gainers: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Dendreon ...  Street Register
NASDAQ Gainers: Celldex Therapeutics (NASDAQ:CLDX), Sunesis ...  Property Mentor
Related articles »